Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Capricor Therapeutics faces a class action alleging it failed to disclose material information to investors during the Dec. 17, 2025–July 26, 2026 period. Separately, FDA briefing documents for the Deramiocel BLA (published July 27, 2026 ahead of a July 29 advisory committee) criticized SAP changes submitted after the pre-specified plan, characterizing analyses as post-hoc/exploratory and noting an unfavorable benefit-risk profile; shares fell $12.70 (-64%) to $7.00 on unusually heavy volume. The lawsuit is pending in the U.S. District Court for the Southern District of California (Nkamga v. Capricor Therapeutics, No. 3:26-cv-04385).

Analysis

The lawsuit itself is not the tradeable event; it is a lagging wrapper around a much larger re-rating in approval probability. Once the regulator signals that the core analysis may be viewed as post-hoc, the market should start discounting not just a delay but a forced reset of the development package, which is far more damaging to equity value than any eventual settlement reserve.

For a small-cap biotech like CAPR, the second-order effect is financing, not litigation. A disputed statistical package reduces partner appetite, raises the probability of a highly dilutive raise, and can push the company into a binary path where either management proves a clean regulatory bridge or the asset becomes a stranded program with minimal recoverable value. That dynamic can keep pressure on the stock for months even after the headline event fades.

The near-term risk is a dead-cat bounce on technical oversold conditions, but the 1-3 month catalyst path still favors sellers unless management delivers a credible FDA interaction, revised analysis, or new clinical rationale. The longer-term bullish case requires the company to restore trust in the endpoint package; absent that, this becomes a capital-structure story rather than a science story. The contrarian risk to shorting is that litigation headlines can get crowded while the stock is already deeply discounted, so timing matters more than directional conviction.

Key Decisions for Investors

• Avoid initiating new long exposure in CAPR until there is a verifiable FDA path forward or a disclosed financing package; the stock can remain structurally impaired for 1-3 months even without fresh negative news.
• If borrow is available and liquidity permits, use any relief rally back toward the high-single digits to add tactical shorts in CAPR with a tight stop above the post-gap recovery zone; thesis is further downside from financing/dilution risk rather than the lawsuit itself.
• For event-driven accounts, consider a small CAPR short against a basket of cleaner biotech names only if borrow and options markets are workable; the relative-value edge is in avoiding name-specific legal/regulatory risk, not in expressing a broad sector view.
• Set an alert for any FDA meeting, CRL, or revised analysis disclosure; a credible regulatory reset would be the key falsifier and could trigger sharp short-covering.